Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma

Access Activity

Overview / Abstract:


Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are FL, an indolent, difficult-to-treat B-cell malignancy (ACS, 2019; NCCN, 2019). Most patients are diagnosed at an average age of 63 years (NCI, 2019). Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common (NCCN, 2019). Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limits the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable (NCCN, 2019).


Community oncologists, hematologists, pathologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with follicular lymphoma.


Upon completion of this activity, participants should be able to:

1.) Evaluate emerging efficacy and safety data on novel therapeutic approaches for patients with relapsed/refractory FL
2.) Discuss the implications of POD24 status in therapeutic decision making for patients with relapsed/refractory FL
3.) Apply strategies to optimize treatment experiences and outcomes for patients with relapsed/refractory FL


Nov 01, 2021


Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

1.0 CME



Presenters / Authors / Faculty

Loretta Nastoupil, MD
Assistant Professor of Medicine
MD Anderson Cancer Center

Reem Karmali, MD, MS
Assistant Professor of Medicine
Northwestern Memorial Hospital

Francisco Vega, MD, PhD
Professor of Pathology
Lymphoma Section Head

Activity Specialities / Related Topics

Hematology, Oncology / Cancer / Radiation Therapy, Pathology

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Epizyme.

Keywords / Search Terms

i3 Health oncology, hematology, pathology, follicular lymphoma, FL, lymphoma, CME, free CME, CE, free CE, ILNA points, free ILNA points, MOC Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map